NCT07136103View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 19, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Healthy Volunteers
Interventions
DRUG

ABBV-277

• Intravenous (IV) infusion

DRUG

Placebo

• Intravenous (IV) infusion

Trial Locations (1)

60030

RECRUITING

Acpru /Id# 265681, Grayslake

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY